A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]
A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]
In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival […]
Papillary renal cell carcinoma (RCC) is a rare form of RCC, occurring in about 10-15% of RCC cases. A recent multi-centre retrospective study looked at the outcomes of patients with metastatic papillary RCC treated with immune checkpoint inhibitors alone. Patients had to have been treated with an immune checkpoint inhibitor, at any time point in […]
This article nicely summarises the most exciting research highlights from the ASCO 2020 Virtual Scientific Programme which demonstrate the evolution of treatments for advanced renal cell carcinoma (RCC), with a focus on combination treatments, salvage therapies and treatments for non-clear cell RCC. Read the review article in the Journal of Clinical Oncology here
A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]
A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]
Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]
In a study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the tyrosine kinase inhibitor (TKI) savolitinib was shown to be more effective and safer than sunitinib as a treatment for people with papillary renal cell carcinoma (RCC). Papillary renal cell carcinoma accounts for approximately 15% of all RCC, making […]
In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
